FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2023246997> ?p ?o ?g. }

• W2023246997 endingPage "S79" @default.
• W2023246997 startingPage "S78" @default.
• W2023246997 abstract "Purpose/Objective: Although prostate cancer often has a relatively good prognosis in terms of mortality, many unanswered questions remain about the morbidity of this disease and its treatment. While a great number of studies have examined health-related quality of life (QOL) following the treatment of prostate cancer, the vast majority of these studies are retrospective or cross-sectional in nature. This research design is not optimal for the analysis of QOL in patients treated for prostate cancer due to significant baseline sexual, urinary, or bowel dysfunction in this cohort. For this reason, prospective studies are much more effective at measuring the QOL in men treated for prostate cancer as they will be more sensitive to changes caused by the cancer or its treatment. This study reports a prospective QOL assessment in patients treated with adjuvant radiotherapy (RT) and two years of androgen suppression (AS) with buserelin acetate for positive surgical margins or persistently elevated PSA in the post-operative period. Given the likelihood that many of these patients will be long term survivors, the QOL implications of this combined therapy are of paramount importance. Materials/Methods: A total of 83 patients were enrolled between 1998 and 2002. QOL data was collected prospectively as a part of a phase II study designed to evaluate the efficacy of combined, sequential, adjuvant RT followed by 2-year AS. All patients had either positive surgical margins or persistently elevated PSA levels after radical prostatectomy. None of the patients had previous hormonal therapy, previous pelvic radiation therapy, or evidence of nodal metastasis on CT. Also, all patients had a negative bone scan, and were not on concurrent cytotoxic medication. Patients completed the EORTC QLQ-C30 questionnaire with the added EORTC prostate cancer module at baseline and at pre-defined follow-up visits. Major QOL domains examined were global health status, erectile function, bowel function, urinary function, as well as the functional and symptom scales of the EORTC QLQ-C30 which include: physical functioning, role functioning, emotional functioning, cognitive functioning, social functioning, fatigue, nausea and vomiting, pain, dyspnoea, insomnia, appetite loss, constipation, diarrhea and financial difficulties. Results: A large decline in bowel function (22%) was observed at the end of RT that was both statistically and clinically significant. Bowel function returned to baseline during AS. There was a decline in global health status and an increase in pain at the end of RT that resolved during AS. While statistically significant, this change was of minor clinical significance. Patients also developed insomnia during AS that was of minor clinical significance and improved during the second year of AS. Interestingly, there was no significant change in either erectile function or urinary function at any time point. None of the other QOL domains of the EORTC QLQ-C30 demonstrated any significant change during either RT or AS compared to the baseline measurement taken at enrollment. Conclusions: Combined adjuvant radiotherapy and androgen suppression following radical prostatectomy results in only a minimal decrease in health-related quality of life compared to the post operative baseline that is worst immediately following RT and improves during AS." @default.
• W2023246997 created "2016-06-24" @default.
• W2023246997 creator A5001199826 @default.
• W2023246997 creator A5010337409 @default.
• W2023246997 creator A5025129662 @default.
• W2023246997 creator A5030206457 @default.
• W2023246997 creator A5030716891 @default.
• W2023246997 creator A5047248767 @default.
• W2023246997 creator A5052506563 @default.
• W2023246997 creator A5064825265 @default.
• W2023246997 creator A5080238562 @default.
• W2023246997 date "2005-10-01" @default.
• W2023246997 modified "2023-09-24" @default.
• W2023246997 title "Quality of Life After Combined Postoperative Adjuvant Radiotherapy and Androgen Suppression for Adenocarcinoma of the Prostate" @default.
• W2023246997 doi "https://doi.org/10.1016/j.ijrobp.2005.07.135" @default.
• W2023246997 hasPublicationYear "2005" @default.
• W2023246997 type Work @default.
• W2023246997 sameAs 2023246997 @default.
• W2023246997 citedByCount "0" @default.
• W2023246997 crossrefType "journal-article" @default.
• W2023246997 hasAuthorship W2023246997A5001199826 @default.
• W2023246997 hasAuthorship W2023246997A5010337409 @default.
• W2023246997 hasAuthorship W2023246997A5025129662 @default.
• W2023246997 hasAuthorship W2023246997A5030206457 @default.
• W2023246997 hasAuthorship W2023246997A5030716891 @default.
• W2023246997 hasAuthorship W2023246997A5047248767 @default.
• W2023246997 hasAuthorship W2023246997A5052506563 @default.
• W2023246997 hasAuthorship W2023246997A5064825265 @default.
• W2023246997 hasAuthorship W2023246997A5080238562 @default.
• W2023246997 hasBestOaLocation W20232469971 @default.
• W2023246997 hasConcept C121608353 @default.
• W2023246997 hasConcept C126322002 @default.
• W2023246997 hasConcept C126894567 @default.
• W2023246997 hasConcept C143998085 @default.
• W2023246997 hasConcept C159110408 @default.
• W2023246997 hasConcept C188816634 @default.
• W2023246997 hasConcept C2776235491 @default.
• W2023246997 hasConcept C2778311097 @default.
• W2023246997 hasConcept C2778559712 @default.
• W2023246997 hasConcept C2779466945 @default.
• W2023246997 hasConcept C2779951463 @default.
• W2023246997 hasConcept C2780192828 @default.
• W2023246997 hasConcept C29456083 @default.
• W2023246997 hasConcept C509974204 @default.
• W2023246997 hasConcept C71924100 @default.
• W2023246997 hasConcept C72563966 @default.
• W2023246997 hasConceptScore W2023246997C121608353 @default.
• W2023246997 hasConceptScore W2023246997C126322002 @default.
• W2023246997 hasConceptScore W2023246997C126894567 @default.
• W2023246997 hasConceptScore W2023246997C143998085 @default.
• W2023246997 hasConceptScore W2023246997C159110408 @default.
• W2023246997 hasConceptScore W2023246997C188816634 @default.
• W2023246997 hasConceptScore W2023246997C2776235491 @default.
• W2023246997 hasConceptScore W2023246997C2778311097 @default.
• W2023246997 hasConceptScore W2023246997C2778559712 @default.
• W2023246997 hasConceptScore W2023246997C2779466945 @default.
• W2023246997 hasConceptScore W2023246997C2779951463 @default.
• W2023246997 hasConceptScore W2023246997C2780192828 @default.
• W2023246997 hasConceptScore W2023246997C29456083 @default.
• W2023246997 hasConceptScore W2023246997C509974204 @default.
• W2023246997 hasConceptScore W2023246997C71924100 @default.
• W2023246997 hasConceptScore W2023246997C72563966 @default.
• W2023246997 hasLocation W20232469971 @default.
• W2023246997 hasOpenAccess W2023246997 @default.
• W2023246997 hasPrimaryLocation W20232469971 @default.
• W2023246997 hasRelatedWork W2014930386 @default.
• W2023246997 hasRelatedWork W2092129431 @default.
• W2023246997 hasRelatedWork W2127440557 @default.
• W2023246997 hasRelatedWork W2154491681 @default.
• W2023246997 hasRelatedWork W2417374591 @default.
• W2023246997 hasRelatedWork W2590008096 @default.
• W2023246997 hasRelatedWork W2979919955 @default.
• W2023246997 hasRelatedWork W3087899116 @default.
• W2023246997 hasRelatedWork W83392053 @default.
• W2023246997 hasRelatedWork W93186087 @default.
• W2023246997 hasVolume "63" @default.
• W2023246997 isParatext "false" @default.
• W2023246997 isRetracted "false" @default.
• W2023246997 magId "2023246997" @default.
• W2023246997 workType "article" @default.